Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

11 déc. 2024 07h01 HE | Source: GEn1E Lifesciences Inc.

GEn1E Lifesciences appoints François Nader, MD as Chair of its Board of Directors

Dr. Nader, current Independent Board Director at Moderna and Senior Advisor at Blackstone Life Sciences, joins GEn1E Lifesciences board as chair.
14 oct. 2024 06h02 HE | Source: GEn1E Lifesciences Inc.

GEn1E Lifesciences Publishes Breakthrough Research Unveiling Novel Mechanism of Action of Dual Signal Modulators for Anti-inflammatory and Endothelial-Stabilizing Therapies

GEn1E Lifesciences today announced the publication of a landmark study in the prestigious Journal of Pharmacology and Experimental Therapeutics (JPET)
19 nov. 2018 12h30 HE | Source: GEn1E Lifesciences Inc.

GEn1E Lifesciences Adds to Development Pipeline with Exclusive Option to License University of Maryland, Baltimore’s MUC1-Ecto-Domain Anti-Bacterial Agent

Provides GEn1E the potential to enter clinic with a therapy for Pseudomonas infections in Cystic Fibrosis patients PALO ALTO, Calif., Nov. 19, 2018 (GLOBE NEWSWIRE) -- GEn1E Lifesciences Inc....
17 oct. 2018 09h30 HE | Source: GEn1E Lifesciences Inc.

GEn1E Lifesciences Granted Exclusive Option to License University of Maryland, Baltimore’s Selective P38 Kinase Inhibitor

Access to University of Maryland, Baltimore’s broadly applicable P38 Kinase inhibitor technology offers GEn1E the potential to enter the clinic with an acute lung injury/acute respiratory distress...